ReviewThe Yale journal of biology and medicine
The biological relevance of gastric neuroendocrine tumors.
Review in The Yale journal of biology and medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 50 citations in OpenAlex.
- Review
- Pretreatment hematologic markers as prognostic predictors of gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis.OncoTargets and therapy · 2018Article
- Early Gastroenteropancreatic Neuroendocrine Tumors: Endoscopic Therapy and Surveillance.Visceral medicine · 2017Review
- Genetic polymorphisms of interleukin 1β gene and sporadic pancreatic neuroendocrine tumors susceptibility.World journal of gastrointestinal oncology · 2016Article
- Histological characterisation and prognostic evaluation of 62 gastric neuroendocrine carcinomas.Contemporary oncology (Poznan, Poland) · 2016Article
- Management of early gastrointestinal neuroendocrine neoplasms.World journal of gastrointestinal endoscopy · 2011Article
- [Gastric neuroendocrine tumors. Endoscopic and surgical treatment].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2011Review
- Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation.The oncologist · 2011Article
- [Neuroendocrine tumors of the stomach. Risk stratification and therapy].Der Pathologe · 2010Article
- Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors.Virchows Archiv : an international journal of pathology · 2007Review
- Endocrine precursor lesions of gastroenteropancreatic neuroendocrine tumors.Endocrine pathology · 2007Review
- Gastrinoma--morphological aspects.Wiener klinische Wochenschrift · 2007Review
- Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features.World journal of gastroenterology · 2006Review
- [Neuroendocrine tumors of the gastrointestinal tract].Der Pathologe · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric neuroendocrine tumors were originally thought to have a low incidence (three percent). Since endoscopic diagnostic procedures have become clinical routine, they are now found more frequently (relative incidence up to 41 percent). In recent years, classifications have been developed that attempt to consider the biological relevance of these tumors. Four types of gastric neuroendocrine tumor may be distinguished: Type 1 gastric neuroendocrine tumor is most common. It is associated with chronic atrophic fundus gastritis, hypergastrinemia and often with pernicious anemia. Usually it is multicentric and smaller than one cm, does not produce any symptoms and has an excellent prognosis. Type 2 gastric neuroendocrine tumor is second in frequency. It has no association with other diseases, is solitary and has no predilection for a particular localization. It may be larger than 1 cm, produce a carcinoid syndrome or Zollinger-Ellison syndrome and have a metastasis rate of up to 30 percent. Type 3 gastric neuroendocrine tumor is rare and always associated with Zollinger-Ellison syndrome and multiple endocrine neoplasia type I. It occurs as multiple lesions in the gastric body fundus and has a lower metastatic rate than type 2 gastric neuroendocrine tumor. Type 4 gastric neuroendocrine tumor corresponds to a small-cell carcinoma.
Indexed as
Identifiers
9041691PMC2588971W2187956876What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.